e-SPACE Cardio-Renal-Metabolic 2022: On-demand

Published: 11 April 2022

  • Views:

    Views Icon 9704

  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 21 | Session 4 of 4
    Panel discussion
    Shelley Zieroth, Giuseppe Rosano
    Up Next
  • episode_image
    Part 6 | Session 1 Introduction Andrew JS Coats, Alice Cheng
  • episode_image
    Part 11 | Session 1 Introduction Mustafa Arici, Pardeep Jhund
  • episode_image
    Part 13 | Session 1 Introduction Fausto J Pinto, Clara Saldarriaga, Stefan Anker
  • episode_image
    Part 13 | Session 3 6.2: Preserved HF Fausto J Pinto, Clara Saldarriaga, Stefan Anker
  • episode_image
    Part 13 | Session 6 Panel discussion Fausto J Pinto, Clara Saldarriaga, Stefan Anker
Average (ratings)
No ratings
Your rating

Overview

e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.

 

The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.

 

This on-demand version of the event comprises:

 

  • Presentations and discussions with leading experts
  • Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
  • Insight to SLGT2i, GLP-1RA and other emerging therapies
  • 'Meet the Expert' sessions

 

e-SPACE Cardio-Renal-Metabolic 2022 was supported by the following companies:

More from this programme

Part 1

Meet the Expert: IgA nephropathy: current optimal management

1 session
Meet the Expert: IgA nephropathy: current optimal management Watch now

Part 2

Session 1: The new KDIGO guidelines

5 sessions
Welcome and introduction Watch now
1.1: BP in CKD Guidelines Watch now
1.2: Diabetes and CKD GL Watch now
1.3: General management of the nephrotic syndrome Watch now
Panel Discussion Watch now

Part 3

Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk

Supported by an unrestricted educational grant from Vifor Pharma
4 sessions
Welcome and Introduction Watch now
Management of iron deficiency in heart failure: new evidence, new guidelines Watch now
Iron deficiency in chronic kidney disease: why iron matters beyond anaemia Watch now
Interactive panel discussion Watch now

Part 4

Session 2: Recent CV guidelines and treatment algorithms

5 sessions
Introduction Watch now
2.1: The new ESC HF guidelines Watch now
2.2: Personalised management Watch now
2.3: Preventive cardiology Watch now
Panel Discussion Watch now

Part 5

Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes

1 session
Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes Watch now

Part 6

Session 3: Management of SGLT2 a practical approach

5 sessions
Introduction Watch now
3.1: Focus on diabetology Watch now
3.2: Focus on cardiology Watch now
3.3: Focus on nephrology Watch now
Panel Discussion Watch now

Part 7

Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist

4 sessions
Introduction Watch now
The meaning of Hemoglobin A1C for the nephrologist Watch now
The meaning of Hemoglobin A1C for the cardiologist Watch now
Panel discussion Watch now

Part 8

Session 4: GLP-1RA and cardio-metabolic disease in diabetes

5 sessions
Introduction Watch now
4.1: GLP-1RA and CVD in diabetes Watch now
4.2: GLP-1 RA and kidney disease in diabetes Watch now
4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA Watch now
Panel discussion Watch now

Part 9

Industry Session: SGLT2 inhibitors in cardio-renal-metabolic disease: optimizing the patient's journey

Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance
6 sessions
Welcome and introduction Watch now
Cardio-renal-metabolic disease in a nutshell Watch now
SGLT2 inhibitors in patients with type 2 diabetes and comorbidities Watch now
SGLT2 inhibitors in patients with heart failure and comorbidities Watch now
SGLT2 inhibitors in patients with chronic kidney disease and comorbidities Watch now
Panel discussion Watch now

Part 10

Session 5: HFpEF: tackling a multidisciplinary problem

6 sessions
Introduction Watch now
5.1: Diagnosis, pathophysiology, epidemiology Watch now
5.2: Diabetes Watch now
5.3: In chronic kidney disease Watch now
5.4: Management with new drugs and devices (CCM, Intra atrial shunts and Cardiomems) Watch now
Panel discussion Watch now

Part 11

Meet the Experts: CKD progression in CVD screening and follow-up

4 sessions
Introduction Watch now
Mechanism of disease interplay between CVD and CKD Watch now
The use of SGLT2is in patients with CKD and CVD with and without diabetes Watch now
Panel discussion Watch now

Part 12

Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM

1 session
Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM Watch now

Part 13

Session 6: New trial update in cardiology

6 sessions
Introduction Watch now
6.1: EMPEROR-Preserved Watch now
6.2: Preserved HF Watch now
6.3: Dronedarone in AF management: A 2022 update Watch now
6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man) Watch now
Panel discussion Watch now

Part 14

Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group

1 session
Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group Watch now

Part 15

Meet the Expert: Multidisciplinary management of cardio-renal-metabolic disease: focus on the kidney

5 sessions
Introduction Watch now
The case for early identification, risk stratification and treatment of CKD Watch now
Protecting the kidney and the heart: the cardiologist's perspective Watch now
Identifying high-risk patients: the primary care physician's perspective Watch now
Panel discussion Watch now

Part 16

Session 8: Sarcopenia, frailty malnutrition and cachexia

5 sessions
Welcome and introduction Watch now
8.1: Cachexia in CV disease Watch now
8.2: Cachexia in CKD Watch now
8.3: Muscle wasting in stroke Watch now
Panel discussion Watch now

Part 17

Meet the Expert: HIF PHI: What do we know and don't know in 2022

1 session
Meet the Expert: HIF PHI: What do we know and don't know in 2022 Watch now

Part 18

Session 9: The cardio-kidney interaction: relevance to diabetes

6 sessions
Introduction Watch now
9.1: Diabetes and CVD today Watch now
9.2: Diabetes and kidney today Watch now
9.3: The cross-talk between kidney and heart Watch now
9.4: Therapeutic solution Watch now
Panel discussion Watch now

Part 19

Industry Session: SGLT2 inhibition in the comorbid CKD patient

Satellite Symposium supported by an unrestricted educational grant from AstraZeneca
2 sessions
SGLT2 inhibition in the comorbid CKD patient Watch now
Panel discussion Watch now

Part 20

Session 10: Why and how to screen for heart failure and kidney disease in diabetes

5 sessions
Introduction Watch now
10.1: Screening of kidney disease Watch now
10.2: Screening of heart failure Watch now
10.3: Horizons opened by the screening Watch now
Panel discussion Watch now

Part 21

Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease

4 sessions
Welcome and introduction Watch now
New developments in SGLT2 inhibitor use in HFrEF and HFpEF Watch now
Implementing guidelines in clinical practice Watch now
Panel discussion Watch now

Part 22

Session 11: SGLT2 inhibition in clinical practice

6 sessions
Introduction Watch now
In ambulatory HFrEF and HFpEF Watch now
When to start after acute decompensation Watch now
Improving QoL and symptoms Watch now
The case of acute MI Watch now
Panel discussion Watch now

Part 23

Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist

1 session
Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist Watch now

Part 24

Session 12: Managing obesity in the CRM setting

6 sessions
Introduction Watch now
Practical issues of managing weight loss in CRM disease: the therapeutic options Watch now
Managing weight loss in CRM disease: the nephrologist's perspective Watch now
Managing weight loss in CRM disease: the diabetologist's perspective Watch now
Managing weight loss in CRM disease: the cardiologists' perspective Watch now
Panel discussion Watch now

Part 25

Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy

3 sessions
Welcome and introduction Watch now
Overcoming barriers to guideline-mandated medical therapy in heart failure the role of long-term potassium control Watch now
Interactive panel discussion Watch now

Part 26

Meet the Expert: SGLT2, the statin of the 21st century

1 session
Meet the Expert: SGLT2, the statin of the 21st century Watch now

Part 27

Session 13: New trial update in nephrology

6 sessions
Introduction Watch now
DAPA CKD: Key lessons from subgroup analyses Watch now
FIDELIO/FIGARO DKD Watch now
FIDELITY - Main lessons including subgroup analyses Watch now
Chlortalidone in CKD stage 4: A new look at an old drug Watch now
Panel discussion Watch now

Part 28

Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options

5 sessions
Introduction Watch now
Screening and diagnosis best practices Watch now
Primary care perspective and challenges Watch now
Reducing CV risks and new treatment options: case discussion Watch now
Panel discussion Watch now

Part 29

Session 14: Telemedicine in CRM

5 sessions
Introduction Watch now
Digital technologies in CV disease Watch now
Remote monitoring of HF Watch now
Telemedicine in CKD from a cardiologist's perspective Watch now
Panel discussion Watch now

Part 30

Session 15: New drugs, new hopes and sometimes risks

5 sessions
Introduction Watch now
Ascend D and ASCEND ND Watch now
The moving field of drug nephrotoxicity Watch now
The role of new potassium binding agents in cardio-renal medicine Watch now
Panel discussion Watch now

Part 31

Meet the Expert: Management of worsening HF

1 session
Meet the Expert: Management of worsening HF Watch now

Part 32

Session 16: Harmonising the gluco-and cardio-centric management of diabetes

5 sessions
Introduction Watch now
Cardio-centric approach Watch now
Gluco-centric approach Watch now
Combination therapy as starting option Watch now
Panel discussion Watch now

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

Director of the Heart Failure and Heart Transplant Clinics

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.

She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of 

View full profile
Giuseppe Rosano

Giuseppe Rosano

Consultant Cardiologist and Professor of Cardiology (Hon)

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.

His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…

View full profile